Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TGTX | TG THERAPEUTICS INC | $5.56B | $35.05 | $57.50 | 64.05% | Strong Buy | 2 | 30.23% | 74.59% | 171.33% | 67.41% | |||
| CORT | CORCEPT THERAPEUTICS INC | $8.09B | $76.81 | $135.33 | 76.19% | Strong Buy | 3 | 28.37% | 47.97% | 128.03% | 101.53% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $2.88B | $38.86 | $50.75 | 30.60% | Strong Buy | 4 | 21.51% | 237.25% | 50.75% | 38.00% | |||
| CRMD | CORMEDIX INC | $719.62M | $10.61 | $18.20 | 71.54% | Buy | 5 | 77.62% | 119.06% | 167.96% | 129.00% | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.76B | $66.36 | $76.14 | 14.74% | Buy | 7 | 16.53% | 25.09% | 308.98% | 50.06% | |||
| KRYS | KRYSTAL BIOTECH INC | $5.59B | $192.99 | $195.57 | 1.34% | Strong Buy | 7 | 32.82% | 29.01% | 29.26% | 26.75% | |||
| RPRX | ROYALTY PHARMA PLC | $21.10B | $36.18 | $46.00 | 27.14% | Strong Buy | 3 | 19.57% | 47.59% | 33.41% | 17.33% | |||
| VCEL | VERICEL CORP | $1.69B | $33.59 | $55.33 | 64.73% | Strong Buy | 3 | 19.25% | 86.18% | 24.59% | 17.32% | |||
| INVA | INNOVIVA INC | $1.10B | $17.39 | $30.75 | 76.83% | Buy | 4 | 12.10% | 60.24% | 26.89% | 14.41% | |||
| ARGX | ARGENX SE | $49.78B | $815.61 | $847.39 | 3.90% | Strong Buy | 13 | 1,391.12% | 9.26% | 36.34% | 30.87% | |||
| EXEL | EXELIXIS INC | $10.78B | $40.03 | $46.31 | 15.70% | Buy | 16 | 10.83% | 18.14% | 69.43% | 52.72% | |||
| ADMA | ADMA BIOLOGICS INC | $3.60B | $15.09 | $32.00 | 112.06% | Strong Buy | 1 | 18.62% | 13.60% | 100.65% | 71.80% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.53B | $26.63 | $45.57 | 71.13% | Strong Buy | 7 | 13.33% | 15.81% | 44.83% | 31.28% | |||
| GYRE | GYRE THERAPEUTICS INC | $854.30M | $8.87 | $17.00 | 91.66% | Strong Buy | 2 | 16.64% | 11.68% | 303.51% | 182.98% | |||
| INCY | INCYTE CORP | $17.21B | $88.15 | $85.36 | -3.16% | Buy | 11 | 8.51% | 22.60% | 42.98% | 30.79% | |||
| TECH | BIO-TECHNE CORP | $9.27B | $59.58 | $68.90 | 15.64% | Strong Buy | 10 | 4.69% | 106.28% | 16.21% | 12.16% | |||
| MDXG | MIMEDX GROUP INC | $992.81M | $6.71 | $12.00 | 78.84% | Strong Buy | 1 | 10.22% | 42.65% | N/A | N/A | |||
| VCYT | VERACYTE INC | $2.72B | $34.78 | $41.50 | 19.32% | Strong Buy | 2 | 8.74% | 51.65% | 7.44% | 6.76% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.19B | $53.09 | $96.71 | 82.17% | Strong Buy | 7 | 7.34% | 17.34% | 21.19% | 17.12% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.51B | $11.47 | $13.00 | 13.34% | Buy | 2 | 10.47% | 14.35% | 20.02% | 13.36% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.60B | $21.26 | N/A | N/A | N/A | N/A | 7.50% | 13.43% | 38.03% | 33.50% | |||
| GMAB | GENMAB A | $20.99B | $32.72 | $43.00 | 31.42% | Strong Buy | 4 | 16.47% | 4.14% | 5.08% | 4.17% | |||
| MNKD | MANNKIND CORP | $1.60B | $5.23 | $11.00 | 110.33% | Strong Buy | 4 | 12.46% | 8.55% | -183.96% | 24.59% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $104.58B | $407.90 | $484.11 | 18.68% | Buy | 18 | 7.28% | 10.03% | 33.80% | 24.15% | |||
| UTHR | UNITED THERAPEUTICS CORP | $19.55B | $432.19 | $495.50 | 14.65% | Buy | 10 | 4.98% | 1.09% | 20.93% | 18.98% | |||
| NVO | NOVO NORDISK A S | $253.25B | $56.72 | $60.50 | 6.66% | Buy | 4 | 1.89% | 1.13% | 97.75% | 34.07% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.